



The Nifty ended 2.65% down at 15809.40. It opened gap-down and continued declining towards finishing off in red with a bearish body candle. Chart pattern suggesting the Benchmark Index may again come down to the most critical support placed around 15750 levels. Breaking down 15750 may lead to further decline towards 15650 levels. Hence, staying cautious on rise is advised. Immediate resistances are placed around 16000 ad 16100 levels.

On the Nifty hourly chart, direction of the leading indicators pointing towards range-bound oscillation in the price band of 15750-16000.

Nifty patterns on multiple periods suggesting; gap down opening suggesting weakness. However, critical support placed in the price range 15750-15650 is still well intact. Intraday pullback towards 16000 is likely.

Nifty Crucial Supports & Resistances-

Supports- 15750, 15650 Resistances- 16000, 16100

Open Positional Calls-

T+10 INST POSITIONAL BUY-

|Cash Segment| AXIS BANK @ 650 -640, TGT- 700, Closing SL- Below 610

T+10 INST POSITIONAL BUY-

|Cash Segment| HDFC BANK @ 1310-1300, TGT- 1400, Closing SL- Below 1250

T+4 BUY-

|Cash Segment| BHEL @ 48, TGT- 52, Closing SL- Below 46

T+10 INST POSITIONAL BUY-

|Cash Segment| SAIL @ 84-83, TGT- 93, Closing SL- Below 78

| Key Contents | Page No. |
|---------------|----------|
| Result Update | 4 |

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks logged one of their worst days of 2022, as markets tumbled after a steep fall in Wall Street caused ripple effects in global equities.

Nifty index ended 2.65% lower at 15,809. The broader markets represented by the Nifty 500 Index ended 2.64% lower, ending at 13,551. Among the sectorial indices every indices ended lower, among them Nifty IT was the top loser losing by 5.74%.

ITC was the top gainer, gaining by 3.32%, followed by Dr. Reddy's Lab and Power Grid which gaining by 0.61% & 0.18%. Wipro was the top loser, losing by 6.25%, followed by HCL Tech and Infosys which losing by 5.99% & 5.44% respectively.

The Advance : Decline ratio stood at 409:1765

Market Turnover (In Crore) 19-05-2022

| Name | Last | Previous |
|----------|----------|-------------|
| NSE Cash | *NA | 59932.35 |
| NSE F&O | *NA | 11311312.73 |
| BSE Cash | 3,856.59 | 3,742.06 |
| BSE F&O | *NA | 231.31 |

FII Derivatives Flow (In Crore) 19-05-2022

| Instrument | Purchase | Sale | Net |
|--------------|------------|------------|----------|
| Index Future | 4838.54 | 5759.31 | 920.77 |
| Index Option | 1056857.01 | 1039952.96 | 16904.05 |
| Stock Future | 19544.89 | 19501.12 | 43.77 |
| Stock Option | 9274.52 | 9296.75 | 22.23 |

Institutional Flow (In Crore) 19-05-2022

| Institution | Purchase | Sale | Net |
|-------------|----------|----------|---------|
| FII | 6389.87 | 11289.79 | 4899.92 |
| DII | 7414.25 | 4188.71 | 3225.54 |

*Data not updated till 7:20PM

NIFTY Top Gainers

| Name | %1D | %5D | Day Vol | Avg 5 Day Vol |
|-----------------|------|------|----------|---------------|
| ITC | 3.32 | 9.00 | 78287713 | 15630300 |
| Dr. Reddy'S Lab | 0.61 | 1.27 | 1825811 | 297113 |
| Power Grid | 0.18 | 3.22 | 11314202 | 12633990 |

NIFTY Top Losers

| Name | %1D | %5D | Day Vol | Avg 5 Day Vol |
|------------------|------|------|----------|---------------|
| TCS | 5.42 | 4.30 | 4642963 | 1962338 |
| Tech Mahindra | 5.43 | 8.61 | 4393100 | 3641155 |
| Infosys | 5.44 | 5.41 | 16561140 | 6602915 |
| HCL Technologies | 5.99 | 4.72 | 4729354 | 2518766 |
| Wipro | 6.25 | 4.78 | 11472989 | 6537480 |

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|----------------|----------|----------|------|------|-------|-------|-------|
| Sensex | 52792.23 | 1416.30 | 2.61 | 0.26 | 7.44 | 8.72 | 6.51 |
| Nifty | 15809.40 | 430.90 | 2.65 | 0.01 | 7.74 | 8.49 | 6.06 |
| BSE M Cap | 22069.73 | 602.43 | 2.66 | 1.96 | 9.74 | 7.16 | 3.39 |
| BSE S Cap | 25801.04 | 603.74 | 2.29 | 3.22 | 10.63 | 7.02 | 12.53 |
| Nifty MC 100 | 27271.90 | 839.80 | 2.99 | 1.72 | 9.93 | 5.75 | 8.17 |
| BSE Auto | 24219.56 | 615.53 | 2.48 | 4.50 | 1.85 | 6.53 | 5.52 |
| BSE Capgoods | 25614.50 | 423.05 | 1.62 | 2.90 | 7.18 | 9.91 | 16.33 |
| BSE FMCG | 13831.59 | 69.98 | 0.50 | 4.28 | 0.20 | 3.21 | 6.70 |
| BSE Metal | 18564.11 | 820.66 | 4.23 | 0.90 | 18.59 | 8.00 | 0.06 |
| BSE Oil&Gas | 18592.03 | 459.55 | 2.41 | 1.10 | 8.25 | 2.83 | 18.48 |
| BSE Healthcare | 22260.05 | 496.51 | 2.18 | 1.20 | 9.14 | 6.60 | 8.90 |
| BSE Power | 4328.10 | 73.43 | 1.67 | 0.42 | 8.87 | 12.09 | 55.40 |
| BSE Realty | 3062.16 | 77.81 | 2.48 | 0.08 | 14.25 | 14.10 | 21.26 |
| BSE ConsDur | 36434.58 | 1036.20 | 2.77 | 0.66 | 14.47 | 14.21 | 12.05 |
| BSE Bank | 38509.51 | 977.75 | 2.48 | 0.59 | 8.12 | 10.57 | 1.68 |
| BSE IT | 28867.82 | 1599.85 | 5.25 | 3.68 | 10.02 | 15.64 | 8.66 |

Bond Markets

| Name | Yield | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|-------------|-------|----------|------|-------|-------|--------|--------|
| US | 2.83 | 0.05 | 1.82 | 0.57 | 3.56 | 46.82 | 69.46 |
| UK | 1.83 | 0.04 | 1.93 | 10.11 | 7.02 | 32.73 | 115.68 |
| Brazil | 5.81 | 0.00 | 0.02 | 0.75 | 7.32 | 13.31 | 51.29 |
| Japan | 0.24 | 0.00 | 0.82 | 2.02 | 2.02 | 12.50 | 196.34 |
| Australia | 3.38 | 0.08 | 2.25 | 1.28 | 10.34 | 50.51 | 90.97 |
| India | 7.32 | 0.03 | 0.44 | 0.04 | 2.36 | 9.88 | 22.53 |
| Switzerland | 0.70 | 0.05 | 6.64 | 0.99 | 25.77 | 162.31 | 662.40 |
| Germany | 0.95 | 0.08 | 7.48 | 13.45 | 4.73 | 396.35 | 966.36 |

Currency

| Name | Rate | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|-----------|--------|----------|------|------|------|-------|-------|
| INR | 77.73 | 0.15 | 0.19 | 0.39 | 1.57 | 4.13 | 5.87 |
| USD Index | 103.31 | 0.50 | 0.49 | 1.47 | 2.32 | 7.56 | 14.54 |
| YUAN | 6.75 | 0.00 | 0.05 | 0.53 | 5.29 | 6.16 | 4.68 |
| GBP | 1.24 | 0.01 | 0.58 | 1.72 | 4.51 | 8.75 | 12.07 |
| EUR | 1.05 | 0.01 | 0.53 | 1.34 | 2.49 | 7.00 | 13.60 |
| YEN | 127.71 | 0.52 | 0.41 | 0.49 | 0.94 | 10.16 | 14.48 |

Freight

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|--------------|---------|----------|------|-------|-------|--------|---------|
| Baltic Dry | 3189.00 | 94.00 | 3.04 | 4.49 | 50.78 | 62.37 | 13.85 |
| Baltic Dirty | 1083.00 | 27.00 | 2.43 | 5.00 | 35.54 | 54.94 | 78.71 |
| SG Dubai HY | 25.00 | 1.35 | 5.12 | 16.92 | 8.46 | 338.60 | 83233.3 |

Global Indices

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|----------------|----------|----------|------|------|-------|-------|-------|
| Dow Jones | 31490.07 | 1164.52 | 3.57 | 1.08 | 9.80 | 7.60 | 7.10 |
| Nasdaq | 11418.16 | 566.37 | 4.73 | 0.47 | 16.16 | 15.72 | 14.15 |
| S&P 500 | 3923.68 | 165.17 | 4.04 | 0.29 | 12.07 | 9.78 | 4.67 |
| FTSE100 | 7265.47 | 171.64 | 2.31 | 0.46 | 4.40 | 3.29 | 4.55 |
| CAC40 | 6225.60 | 127.36 | 2.00 | 0.31 | 4.73 | 10.16 | 0.59 |
| DAX | 13744.84 | 260.54 | 1.86 | 0.06 | 2.87 | 8.61 | 9.04 |
| Mexico IPC | 50394.03 | 1070.00 | 2.08 | 2.27 | 7.76 | 3.61 | 2.05 |
| Brazil Bovespa | 106247.2 | 0.00 | 0.00 | 1.77 | 7.66 | 5.88 | 13.36 |
| Russian RTS | 1235.37 | 22.71 | 1.87 | 8.35 | 32.56 | 11.21 | 20.45 |
| Japan Nikkei | 26402.84 | 508.36 | 1.89 | 2.54 | 2.99 | 2.65 | 6.03 |
| Hang Seng | 20120.68 | 523.60 | 2.54 | 3.82 | 3.93 | 17.29 | 29.28 |
| Taiwan Index | 16020.32 | 276.54 | 1.70 | 2.58 | 6.58 | 12.13 | 0.14 |
| Shanghai Comp | 3096.97 | 10.99 | 0.36 | 1.37 | 1.72 | 11.28 | 11.69 |
| KOSPI | 2592.34 | 33.64 | 1.28 | 1.66 | 4.65 | 5.54 | 18.02 |
| Malaysia KLCI | 1549.41 | 5.50 | 0.35 | 0.42 | 2.78 | 3.35 | 1.64 |
| Jakarta Comp | 6823.34 | 29.92 | 0.44 | 0.10 | 5.59 | 1.01 | 17.69 |
| Philippine SE | 6660.05 | 67.55 | 1.00 | 1.96 | 6.75 | 10.23 | 7.46 |
| Thai Exch | 1605.98 | 14.35 | 0.89 | 0.46 | 4.43 | 6.26 | 3.31 |

Indian Indices

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|-------------|--------|----------|------|------|-------|-------|--------|
| NYMEX Crude | 107.88 | 1.71 | 1.56 | 1.65 | 5.19 | 18.46 | 70.27 |
| BRENT Crude | 108.00 | 1.13 | 1.04 | 0.49 | 1.27 | 22.22 | 72.38 |
| Natural Gas | 8.15 | 0.22 | 2.59 | 5.32 | 12.01 | 83.46 | 211.94 |

LME

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|------------------|---------|----------|------|------|-------|-------|-------|
| Gold(\$/Ounce) | 1830.14 | 13.27 | 0.73 | 0.44 | 6.16 | 3.61 | 2.13 |
| Silver(\$/Ounce) | 21.68 | 0.25 | 1.15 | 4.79 | 13.95 | 9.42 | 21.87 |
| Aluminium | 2838.76 | 25.99 | 0.91 | 3.41 | 13.23 | 13.95 | 15.97 |
| Copper | 9250.10 | 136.15 | 1.45 | 1.16 | 10.17 | 7.59 | 10.85 |
| Zinc | 3629.00 | 36.25 | 0.99 | 1.48 | 18.91 | 0.80 | 19.49 |
| Lead | 2041.25 | 44.25 | 2.12 | 3.04 | 16.35 | 13.54 | 8.08 |

Agro Commodities

| Name | Price | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|---------|---------|----------|------|------|------|-------|-------|
| Coffee | 215.90 | 1.70 | 0.78 | 0.28 | 2.62 | 11.77 | 35.57 |
| Cotton | 128.21 | 0.97 | 0.75 | 0.42 | 6.00 | 24.73 | 68.39 |
| Sugar | 19.66 | 0.17 | 0.86 | 5.47 | 0.05 | 12.21 | 24.67 |
| Wheat | 1213.75 | 17.00 | 1.38 | 2.97 | 9.45 | 51.58 | 83.83 |
| Soybean | 1670.00 | 7.25 | 0.44 | 3.49 | 1.29 | 4.31 | 24.37 |

Finolex Ind

Finolex Ind reported standalone quarterly numbers, Net Sales at Rs 1,594.57 crore in March 2022 up 27.63% from Rs. 1,249.34 crore in March 2021. Quarterly Net Profit at Rs. 493.80 crore in March 2022 up 66.08% from Rs. 297.33 crore in March 2021. EBITDA stands at Rs. 289.42 crore in March 2022 down 31.67% from Rs. 423.59 crore in March 2021. Finolex Ind EPS has increased to Rs. 7.96 in March 2022 from Rs. 4.79 in March 2021.

Granules India

Granules India reported standalone quarterly numbers, Net Sales at Rs 1,029.97 crore in March 2022 up 28.86% from Rs. 799.31 crore in March 2021. Quarterly Net Profit at Rs. 111.00 crore in March 2022 down 12.99% from Rs. 127.57 crore in March 2021. EBITDA stands at Rs. 196.66 crore in March 2022 down 4.2% from Rs. 205.29 crore in March 2021. Granules India EPS has decreased to Rs. 4.48 in March 2022 from Rs. 5.15 in March 2021.

JK Lakshmi Cement

JK Lakshmi Cement reported standalone quarterly numbers, Net Sales at Rs 1,599.83 crore in March 2022 up 12.32% from Rs. 1,424.32 crore in March 2021. Quarterly Net Profit at Rs. 183.73 crore in March 2022 up 20.16% from Rs. 152.91 crore in March 2021. EBITDA stands at Rs. 340.51 crore in March 2022 up 0.01% from Rs. 340.47 crore in March 2021. JK Lakshmi Cem EPS has increased to Rs. 15.81 in March 2022 from Rs. 12.99 in March 2021.

LIC Housing Finance

LIC Housing Finance's net profit rose by 180 per cent to Rs 1,118.6 crore for the fourth quarter ended March 2022 (Q4 FY22), gaining from an increase in net interest income and sharp dip in credit costs. It had posted a net profit of Rs 398.92 crore in Q4 FY21. However, its net profit for FY22 fell to Rs 2,287.28 crore from Rs 2,734.34 crore in FY21. The Net Interest Income (NII) rose by nine per cent to Rs 1,637 crore in Q4FY22, as against Rs 1,505 crore in Q4FY21. The Net Interest Margin were flat at 2.65 per cent as against 2.66 per cent for Q4FY21. The amounts set aside for impairment on financial instruments declined sharply to Rs 176.93 crore in Q4FY22 from Rs 977.19 crore in Q4FY21. The total disbursements were lower at Rs 19,315 crore in Q4 FY 22, as against Rs 22,362 crore in Q4 FY21.

Lupin

Lupin posted a net loss of Rs 511.9 crore for the fourth quarter of fiscal 2021-22 due to rising costs, price erosion in the US and impairment expense of Rs 126.7 crore for US-based Gavis. Lupin had posted a net profit of Rs 464 crore in the corresponding quarter last fiscal. Sales were up by 2.8 percent YoY to Rs 3,864.5 crore. EBITDA for the quarter was down 63 percent to Rs 282 crore. For the full year, Lupin posted a net loss of Rs 1,509 crore compared to a net profit of Rs 1226 crore in FY21. Sales for the full year grew by 8.5 percent to Rs 16192.8 crore.

Manappuram Finance

Manappuram Finance reported over 44 per cent decline in net profit at Rs 261 crore in the quarter ended March 2022. The company had posted a net profit of Rs 468 crore in the same quarter of the previous year. The company's net interest income also fell by 10.2 per cent in the March quarter of FY22 to Rs 986.50 crore as against Rs 1,098.40 crore in the year-ago period. It was up by 3.5 per cent from previous quarter's Rs 953.40 crore. The income from operations were down by 8.7 per cent, at Rs 1,481.40 crore during the quarter from Rs 1,484.5 crore.

Pidilite Industries

Pidilite Industries reported a 17.7% fall in consolidated net profit to Rs 254.35 crore in Q4 FY22 compared with the net profit of Rs 308.89 crore in Q4 FY21. Net sales stood at Rs 2,507.10 crore for the quarter ended 31 March 2022 as against Rs 2,235.52 crore during the same period in the previous year, registering a growth of 12.1%. Profit before tax stood at Rs 345.87 crore in the fourth quarter, down by 15.9% from Rs 411.19 crore in the same period last year. The company reported a 18.4% jump in total expenditure to Rs 2,106.02 crore in Q4 FY22 over Q4 FY21. EBITDA for the quarter ended stood at Rs 412 crore, which is lower by 11% over the same quarter last year.

Dr Reddy's Laboratories

Net profit of Dr Reddy's Laboratories declined 82.59% to Rs 97.00 crore in the quarter ended March 2022 as against Rs 557.30 crore during the previous quarter ended March 2021. Sales rose 14.98% to Rs 5436.80 crore in the quarter ended March 2022 as against Rs 4728.40 crore during the previous quarter ended March 2021. For the full year, net profit rose 11.83% to Rs 2182.50 crore in the year ended March 2022 as against Rs 1951.60 crore during the previous year ended March 2021. Sales rose 13.00% to Rs 21439.10 crore in the year ended March 2022 as against Rs 18972.20 crore during the previous year ended March 2021.

Gland Pharma

Net profit of Gland Pharma rose 9.79% to Rs 285.90 crore in the quarter ended March 2022 as against Rs 260.41 crore during the previous quarter ended March 2021. Sales rose 24.25% to Rs 1103.01 crore in the quarter ended March 2022 as against Rs 887.75 crore during the previous quarter ended March 2021. For the full year, net profit rose 21.54% to Rs 1211.66 crore in the year ended March 2022 as against Rs 996.96 crore during the previous year ended March 2021. Sales rose 27.08% to Rs 4400.71 crore in the year ended March 2022 as against Rs 3462.88 crore during the previous year ended March 2021.

Hindustan Petroleum Corporation

Net profit of Hindustan Petroleum Corporation declined 40.51% to Rs 1795.26 crore in the quarter ended March 2022 as against Rs 3017.96 crore during the previous quarter ended March 2021. Sales rose 30.43% to Rs 97226.51 crore in the quarter ended March 2022 as against Rs 74544.62 crore during the previous quarter ended March 2021. For the full year, net profit declined 40.15% to Rs 6382.63 crore in the year ended March 2022 as against Rs 10663.88 crore during the previous year ended March 2021. Sales rose 50.24% to Rs 348427.79 crore in the year ended March 2022 as against Rs 231913.35 crore during the previous year ended March 2021.

Bosch

Bosch reported a 27.28% fall in consolidated net profit to Rs 350.5 crore in Q4 FY22 from Rs 482 crore posted in Q4 FY21. Revenue from operation stood at Rs 3,311 crore for the quarter ended 31 March 2022 as against Rs 3,215.9 crore during the same period in the previous year, registering a growth of nearly 3%. Profit before tax stood at Rs 431.4 crore in the fourth quarter, down by 32.59% from Rs 640 crore in the same period last year. The company reported a 10.37% rise in total expenses to Rs 2,972.2 crore in Q4 FY22 over Q4 FY21. On full year basis, the company recorded 153.17% surge in net profit to Rs 1,217 crore on a 21.26% rise in revenue from operations to Rs 11,781.6 crore in the year ended 31 March 2022 over the year ended 31 March 2021.

Ashok Leyland

Ashok Leyland reported net standalone profits for the quarter ended March stood at Rs 901.37 crore, up 273.74 per cent from Rs 241.17 crore in the same quarter last year. Revenue from operation of the Hinduja Group firm climbed 24.90 per cent from Rs 7,000.49 crore to Rs 8744.29 crore in the corresponding quarter last year. The operating margin was at 8.87 per cent, compared to 7.63 per cent in the year-ago quarter and 4.04 per cent in the previous quarter. Net profit margin increased to 10.31 per cent from 3.45 per cent and 0.10 per cent, respectively. Ashok Leyland's truck market share for Q4FY22 improved to 30.6 per cent vis-à-vis 28.9 per cent in Q4FY21. This is the highest market share seen in the last 11 quarters.

Alkyl Amines Chemicals

Net profit of Alkyl Amines Chemicals declined 49.87% to Rs 46.42 crore in the quarter ended March 2022 as against Rs 92.60 crore during the previous quarter ended March 2021. Sales rose 11.39% to Rs 425.64 crore in the quarter ended March 2022 as against Rs 382.13 crore during the previous quarter ended March 2021. For the full year, net profit declined 23.85% to Rs 224.89 crore in the year ended March 2022 as against Rs 295.34 crore during the previous year ended March 2021. Sales rose 24.18% to Rs 1542.80 crore in the year ended March 2022 as against Rs 1242.44 crore during the previous year ended March 2021.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

| Company | Details |
|---------------------------------|---|
| Trent Ltd | Cash dividend of INR1.10 effective 20-05-22 |
| Kewal Kiran Clothing Ltd | Cash dividend of INR5 effective 20-05-22 |
| Krishna Ventures Ltd | Corporate meeting effective 20-05-22 |
| Continental Petroleum Ltd/India | Corporate meeting effective 20-05-22 |
| La Tim Metal & Industries Ltd | 10 for 1 Stock split effective 20-05-22 |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Domestic Events

- India Foreign Exchange Reserve for May 13, 2022.

Global Events

- Euro Area Consumer Confidence for May 2022.

Analyst Certification:

We /I, Jaydeb Dey and Shreyansh N. Mehta Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
